News

2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Resverlogix Intends to Pursue U.S. Listing
Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer’s Disease (CTAD) Asia and Alzheimer’s Association International Conference (AAIC)
Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
Resverlogix Announces Withdrawal of Public Offering of Units
Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kill” Approach
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
Resverlogix Announces Lifting by TSX of Review
Resverlogix Closes US$30 Million Loan
Resverlogix Advances US$30 Million Loan Closing Documentation
Resverlogix Announces Proposed Offering of Units
Resverlogix Announces TSX Review Update
Resverlogix Announces US$30 Million Loan Commitment Letter
Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial
Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Resverlogix Highlights Key Accomplishments and 2018 Targets
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement